G
George E. Loss
Researcher at University of Queensland
Publications - 95
Citations - 3023
George E. Loss is an academic researcher from University of Queensland. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 29, co-authored 95 publications receiving 2747 citations. Previous affiliations of George E. Loss include University of Arkansas for Medical Sciences & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis
TL;DR: In conclusion, more frequent surveillance for HCC may be warranted in obese patients with alcoholic and cryptogenic cirrhosis, as this study is based on patients with advanced Cirrhosis and findings need to be confirmed in a broader population of individuals with cirrhotic disease.
Journal ArticleDOI
Complications in 100 living-liver donors.
Hani P. Grewal,Jill Thistlethwaite,George E. Loss,J. S. Fisher,David C. Cronin,Christopher T. Siegel,K A Newell,D. S. Bruce,E. S. Woodle,Lynda Brady,Susan Kelly,Pamela Boone,Katherine Oswald,J M Millis +13 more
TL;DR: Although the procedure is safe, many LDLT donors have a perisurgical complication, however, and to minimize the risks for these healthy donors, LDLT should be performed at institutions with extensive experience.
Journal ArticleDOI
Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.
TL;DR: Steroid-free liver transplantation using RATG and early tacrolimus monotherapy effectively reduces immunosuppression-related complications with excellent survival and there was a trend toward decreased severity of hepatitis C virus in the R ATG group.
Journal ArticleDOI
Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial
TL;DR: RATG induction enables complete avoidance of steroid use in OLT with a trend toward a lower rejection rate, decreased incidence of post‐OLT diabetes and recurrent hepatitis C, and decreased CMV infection.
Journal ArticleDOI
Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey.
C.C. Otley,D. Berg,C. Ulrich,T. Stasko,G.M. Murphy,S.J. Salasche,L. J. Christenson,R. Sengelmann,George E. Loss,J. Garces +9 more
TL;DR: Reduction of immunosuppression is considered a reasonable adjuvant therapeutic strategy in solid‐organ transplant recipients experiencing multiple or high‐risk skin cancers, but the literature provides no guidance about what threshold of cancer development would warrant initiation of reduction of immunOSuppression.